HNSA (, %) SEK
Hansa Biopharma logotyp

Hansa Biopharma AB launches new name and unveils logo

Lund, Sweden, February 1, 2019 – Hansa Biopharma AB, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today formally launched the Company’s new name. In December, the Company, formerly known as Hansa Medical AB, announced the name change had been approved by the ‘Bolagsverket’ in Sweden and that its stock ticker symbol had changed from “HMED” to “HNSA” on Nasdaq Stockholm.

Søren Tulstrup, CEO of Hansa Biopharma, comments: “Our new name, Hansa Biopharma, represents the next stage in the Company’s lifecycle and emphasizes our focus on the development and commercialization of biopharmaceuticals. The Hansa Biopharma logo expresses optimism and inspiration. Its dynamic form reflects the idea of a ‘hansa’ as a group of skilled individuals combining for a greater purpose, shining outward to represent the benefits we aim to deliver via our enzymology platform to people affected by a rare immunopathology.

The corporate website, at the new address of, will fully reflect the new identity over the coming weeks.

This change follows the approval, by the Bolagsverket in Sweden, of resolutions approved at an Extraordinary General Meeting ("EGM") held on December 4, 2018.

The information was submitted for publication, through the agency of the contact person set out below, at 8:00 am CET on February 1, 2019.